
Sequel Pharma and Microbix Biosystems have formally reconfirmed their agreement to reintroduce Kinlytic® urokinase to the market, initially targeting the dissolution of blood clots obstructing venous catheters in the United States. Microbix has received an additional US$ 2.0 million from Sequel Pharma as part of this reconfirmation. Kinlytic, an enzyme sourced from human cell cultures, already holds U.S. clinical approval. The collaboration aims to validate new manufacturing processes through a supplemental biologics licensing application (sBLA). The sequel will fund and execute the required work, targeting a US$ 350 million annual market for Catheter Clearance. The project's progress will impact Microbix's financials in Q4 2023 and Q1 2024.
Like
Save
Share